Less Paravalvular Regurgitation and More Pacemakers for the New Balloon Expandable Valve

Original Title: Changes in the Pacemaker Rate After Transition from Edwards SAPIEN XT to SAPIEN 3 Transcatheter Aortic Valve Implantation. The Critical Role of Valve Implantation Height. Reference: Fernando De Torres-Alba et al. J Am CollCardiolIntv. 2016, online before print.

 

The aim of this study was to analyze pacemaker implantation rates with the new generation balloon expandable Edwards SAPIEN 3 valve and the possible factors associated to this event.

The introduction of the new generation Edwards SAPIEN lead to a reduction of paravalvular regurgitation, but there is concern that definite pacemaker rates may increase.

The first 206 patients receiving the new Edwards SAPIEN S3 were compared to 371 preceding patients receiving the previous generation valve SAPIEN XT.

Those that had previously received a pacemaker,or transapical, or valve in valve procedures, were excluded.

All conduction abnormalities, both new and old, were documented, as well as implantation height. All patients were monitored at least 7 days. There were no significant differences between baseline characteristics in the two populations.

Pacemaker implantation rate was significantly higher with the new generation valve (19.1% vs. 12.2%; p = 0.046). Implantation height was lower in those receiving pacemakers and this point resulted the only independent factor in multivariable analysis (OR 0.94 CI 95% 0.90 to 0.99; p = 0.009).

We can use the native annulus as reference to measure what percentage of the transcatheter valve stent is above the annulus in the aorta, and what percentage is in the ventricle, below the annulus.

An increased percentage in the ventricle was observed that could explain the higher pacemaker rate. This ratio went from 68%/32% (aorta/ventricle) in the first cases with SAPIEN S3to 75%/25% (aorta/ventricle)in the last cases, which is significant(p < 0.0001). This change in implantation height was associated with a difference in pacemaker rate (25.9% vs 12.3; p = 0.028).

Conclusion
Pacemaker implantation rate with the new generation balloon expandable SAPIEN S3 valve resulted higher compared to the previous generation SAPIEN XT. This increase could be avoided if the valve stent is >70% above the annulus.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...